MedImmune LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1987-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://medimmune.com
A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That MEDI0382 is Well Tolerated
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-06-08
- Last Posted Date
- 2020-04-13
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 41
- Registration Number
- NCT03550378
- Locations
- 🇬🇧
Research Site, Edinburgh, United Kingdom
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2018-05-21
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 401
- Registration Number
- NCT03530397
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2018-04-05
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 107
- Registration Number
- NCT03489525
- Locations
- 🇪🇸
Research Site, Badalona, Spain
Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 49
- Registration Number
- NCT03444584
- Locations
- 🇬🇧
Research Site, Rotherham, United Kingdom
A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent
- First Posted Date
- 2017-12-28
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 32
- Registration Number
- NCT03385369
- Locations
- 🇺🇸
Research Site, Anaheim, California, United States
Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2017-12-21
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 43
- Registration Number
- NCT03381274
- Locations
- 🇨🇳
Research Site, Taichung, Taiwan
A 6-Part Study In Healthy Volunteers To Evaluate Safety, Tolerability and Uptake Of MEDI7219 in the Body When Given as Single and Multiple Doses
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2020-08-31
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 186
- Registration Number
- NCT03362593
- Locations
- 🇬🇧
Research Site, Ruddington, United Kingdom
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Adults With Stable Coronary Heart Disease
- First Posted Date
- 2017-11-24
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 133
- Registration Number
- NCT03351738
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-11-20
- Last Posted Date
- 2018-04-25
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 22
- Registration Number
- NCT03347968
- Locations
- 🇺🇸
Research Site, Daytona Beach, Florida, United States
A Pilot Study Investigating Bioequivalence Between a Single Dose of Formulation 2 and Formulation 3 of MEDI0382
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2018-02-14
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 24
- Registration Number
- NCT03341013
- Locations
- 🇺🇸
Research Site, Dallas, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath